Brief: Horizon Therapeutics PLC Doses First Patient In Phase 2 Trial Of Bempikibart For Severe Alopecia Areata
13/09/2023 13:50
Sept 13 (Reuters) - Horizon Therapeutics PLC HZNP.O :
* Q32 BIO AND HORIZON THERAPEUTICS PLC ANNOUNCE DOSING OF
FIRST
PATIENT IN PHASE 2 TRIAL OF BEMPIKIBART (FORMERLY ADX-914) FOR
SEVERE ALOPECIA AREATA
Source text for Eikon: ID:nBwbtyczDa
Further company coverage: HZNP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Horizon Therapeutics
See all newsDeals of the day-Mergers and acquisitions
Amgen completes $27.8 bln Horizon deal (updated)
Amgen completes acquisition of Horizon Therapeutics
Brief: Amgen Completes Acquisition Of Horizon Therapeutics PLC
On October 5, Court Sanctioned The Scheme Of Arrangement Under Chapter 1 Of Part 9 Of The Irish Companies Act 2014